SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wang MC, Valenzuela LA, Murphy GP et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 15963
  • 2
    Ferro MA, Barnes I, Roberts JBM et al. Tumour markers in prostatic carcinoma: a comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987; 60: 6973
  • 3
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661
  • 4
    Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 8415
  • 5
    Kuriyama M, Wang MC, Papsidero LD et al. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 465862
  • 6
    Seamonds B, Yang N, Anderson K et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase as for prostate cancer markers. Urology 1986; 28: 4729
  • 7
    Kuriyama M, Wang MC, Lee CL et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 1982; 68: 99105
  • 8
    Cooner WH, Mosley BR, Rutherford CL Jr et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 114652
  • 9
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004; 350: 223946
  • 10
    Mochtar CA, Kiemeney LALM, van Riemsdijk MM et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695700
  • 11
    Schroder FH, van der Cruijsen-Koeter I, de Koning HJ et al. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 80612
  • 12
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004; 350: 223946
  • 13
    Tang P, Sun L, Uhlman MA et al. Initial prostate specific antigen 1.5 ng/mL or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 2010; 183: 94651
  • 14
    Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cut off of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 46974
  • 15
    Hughes A, O’Donnell C, Tandberg DJ, Crawford ED. Use of a 1.5 PSA threshold to identify increased risk for prostate cancer in a screening population. Abstract presented at American Urological Association Annual Meeting, San Francisco, 29 May to 3 June, 2010
  • 16
    Schroder FH, Raaijmakers R, Postma R et al. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005; 174: 48994; discussion 493–4
  • 17
    Van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF et al. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial ERSPC Rotterdam. Urology 2006; 68: 61520
  • 18
    Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prevent Chronic Dis 2007; 4: 117
  • 19
    Crawford ED, Pinsky PF, Chia D et al. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2006; 175: 128690; discussion 1290
  • 20
    Crawford ED, Wilson SS, McConnell JD et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 14226
  • 21
    Marberger MJ, Andersen JT, Nickel JC et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 5638
  • 22
    Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predicts long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 6629
  • 23
    Bartsch G, Fitzpatrick JM, Schalken JA et al. Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl. 1): 279
  • 24
    Crawford ED, Tandberg DJ, Sullivan KF et al. Medical therapy use among men at increased risk of BPH progression based on the PSA threshold of 1.5 ng/mL or greater: an analysis of data from the Prostate Cancer Awareness Week screening program. Abstract presented at American Urological Association Annual Meeting, Chicago, April 25–30, 2009
  • 25
    Punglia RS, D’Amico AV, Catalona WJ et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 33542
  • 26
    Wilson SS, Crawford ED. Screening for prostate cancer. Clin Prostate Cancer 2004; 3: 215. Review
  • 27
    Hakama M, Stenman UH, Aromaa A et al. Validity of the prostate specific antigen test for prostate cancer screening: a followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166: 218991
  • 28
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 28994
  • 29
    Carter HB, Ferrucci L, Kettermann A et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98: 15217
  • 30
    Lilja H, Ulmert D, Björk T et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25: 4316